


Efficacy & Safety

The Power of ANKTIVA®

ANKTIVA is an interleukin-15 (IL-15) superagonist, which is a type of immunotherapy that causes natural killer and T cells to increase in numbers and become more active without activating immunosuppressive T reg cells.

The efficacy outcome measures for the QUILT 3.032 study were complete response (CR) at any time, defined as negative cystoscopy and urine cytology, and duration of response.



Duration of Response

53+ Months

Meaning some study participants remained NMIBC-free for over 4 years¹

+ Denotes an ongoing response

% of Responders Who Were Cystectomy Free At 36 Months^{1,2}

84%

Disease-Specific Overall Survival at 36 Months^{1,2}

99%

The following dataset reflects an updated follow up of the 77 patients in the ANKTIVA prescribing information demonstrating the durability of response of ANKTIVA plus BCG.¹

Kaplan Meier (KM) Duration of Complete Response

12 Month DOR

69%

95% CI (53/80)

24 Month DOR

66%

95% CI (50/78)

36 Month DOR

59%

95% CI (41/72)

45 Month DOR

51%

95% CI (33/66)

[Learn More about Kaplan Meier Duration of Complete Response¹](#)

1. Chang, S. (2025, April 26-29). An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.

2. These data on time to cystectomy and disease specific survival represent prespecified secondary endpoints in QUILT-3.032. These results should be interpreted with caution and in the context of the study's limitations of a single-arm study.

Adverse Reactions Occurring in ≥15% of Patients in Cohort A IN QUILT-3.032

Adverse Reaction	ANKTIVA with BCG1 (n=88)	
	one	two
Dysuria	32	0
Hematuria ¹	32	3.4
Urinary	27	0
Micturition Urgency ¹	25	0
Urinary Tract Infection ¹	24	2.3
Musculoskeletal Pain ¹	17	2.3
Chills	15	0
Pyrexia	15	0

1. Includes other related terms

Clinically relevant adverse reactions in <15% of patients who received ANKTIVA with BCG included fatigue (14%), nausea (14%), bladder irritation (11%), diarrhea (9%), and nocturia (7%).

Efficacy Results in QUILT-3.032

ANKTIVA with BCG1 (n=88)	
Complete Response Rate (95% CI)	62% (51, 73)
Duration of Response ^a	
Range in months	0.0, 47.0+
% (n) with duration ≥ 12 months	58% (28)
% (n) with duration ≥ 24 months	40% (19)

+. Denotes ongoing response

a. Based on 48 patients that achieved a complete response at any time; reflects period from the time complete response was achieved





Indication and Important Safety Information

Efficacy & Safety

A clinical resource highlighting key efficacy and safety information about ANKTIVA (nogapendekin alfa inbakicept-pmln)

[Download PDF](#)

ANKTIVA: How to Order

A step-by-step guide on how to order ANKTIVA, including product codes

[Download PDF](#)

Patient Stories

Read about patients who participated in the clinical trials for ANKTIVA



Justin's Journey

An avid outdoorsman, Justin faced a challenging diagnosis of non-muscle invasive bladder cancer. After struggling with the side effects of his Bacillus Calmette-Guérin (BCG) treatment, he found renewed hope through his doctors' introduction to an immunotherapy for those who experienced a recurrence of NMIBC.

[Learn More →](#)



Wayne's Journey

Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who "just likes people". When he was first told, "you might have a tumor in your bladder", he became very concerned, especially when he learned his first treatment with BCG wasn't working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.

[Learn More →](#)

[See All Stories](#)

ANKTIVA Resources

Information for ANKTIVA



Indication and Important Safety Information

[DATASHEET](#)

[ANKTIVA: Efficacy & Safety](#)



[DATASHEET](#)

[ANKTIVA: Mechanism of Action](#)



[DATASHEET](#)

[ANKTIVA: How to Order](#)



[VIDEO](#)

[Physicians' Journey](#)



Safety

A clinical resource highlighting key efficacy and safety information about ANKTIVA (nogapendekin alfa inbakicept-pmIn)

[Download PDF](#)

Action

A description of how BCG and ANKTIVA work together in NMIBC CIS

[Download PDF](#)

A step-by-step guide on how to order ANKTIVA, including product codes

[Download PDF](#)

Listen to the physicians' journey with their patients using ANKTIVA.

[Watch Video](#)

[See All Resources](#)

Indication and Important Safety Information

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common ($\geq 15\%$) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktivastg.wpenginpowered.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact ImmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA is a Novel Treatment for NMIBC CIS Patients Unresponsive to BCG

For more information, please call 1-877-ANKTIVA



Why is ANKTIVA® Right for You?

ANKTIVA is an Immunotherapy that Activates Your Body's Cancer Fighting Cells

ANKTIVA is the first U.S. FDA-approved immunotherapy that activates a type of cell called a natural killer (NK) cell, part of the body's natural immune system, to attack and kill non-muscle invasive bladder cancer (NMIBC) cells.¹ ANKTIVA is a treatment for use in combination with a standard treatment for NMIBC, bacillus Calmette-Guérin (BCG), for people with NMIBC for whom BCG alone was not effective or in whom NMIBC returned after initial successful treatment. These people have what is termed BCG-unresponsive NMIBC. ANKTIVA plus BCG is an option for people with BCG-unresponsive NMIBC carcinoma in situ (CIS) who are unable or unwilling to have their bladder surgically removed.



84%

of patients who responded to ANKTIVA were able to keep their bladders at 36 months^{1,2}

(n=100)

71%

of study participants had a complete response, meaning their cancer was eliminated¹

(n=100)(95% CI=61.179.6)

53+ Months

Duration of Response, meaning some study participants remained NMIBC-free for over 4 years¹

99%

Disease-Specific Overall Survival at 36 Months^{1,2}

1. Chang, S. (2025, April 26-29). An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.

2. These data on time to cystectomy and disease specific survival represent prespecified secondary endpoints in QUILT-3.032. These results should be interpreted with caution and in the context of the study's limitations of a single-arm study.





Who Should Consider ANKTIVA?

ANKTIVA is a treatment for adults who have all the following:

- High-risk non-muscle invasive bladder cancer
- NMIBC that did not or is no longer responding to BCG therapy alone (BCG-unresponsive)
- NMIBC that has not grown beyond the inner lining of the bladder to the muscle underneath (called carcinoma in situ or CIS disease)
- NMIBC with or without small finger-like tumor growths that project away from the bladder wall into the bladder (papillary disease)

If You Have Been Diagnosed with BCG-Unresponsive NMIBC CIS Disease and are Interested in ANKTIVA, Here is What You Need to Know:

What ANKTIVA is



ANKTIVA is an immunotherapy that activates your body's cancer fighting cells



ANKTIVA is used in combination with BCG and is administered directly into your bladder via a catheter



ANKTIVA is the first treatment of its type approved to treat BCG-unresponsive NMIBC



ANKTIVA can be administered in a clinical setting and allows you to remain in the care of your urologist

What ANKTIVA is not



ANKTIVA is not a chemotherapy or gene therapy



ANKTIVA is not administered via an IV and does not circulate throughout your body. It only fights cancer in the bladder. This may reduce side effects



ANKTIVA is *not* a chemical, it is a biologic that is similar to molecules produced naturally by your body



ANKTIVA does not require you to change providers for treatment



Getting Started with ANKTIVA for Patients

A patient-friendly overview of how ANKTIVA plus BCG work together, as well as what patients should expect before and after treatment

[Download](#)

Patient Stories

Read about patients who participated in the clinical trials for ANKTIVA



Justin's Journey

An avid outdoorsman, Justin faced a challenging diagnosis of non-muscle invasive bladder cancer. After struggling with the side effects of his Bacillus Calmette-Guérin (BCG) treatment, he found renewed hope through his doctors' introduction to an immunotherapy for those who experienced a recurrence of NMIBC.

[Learn More →](#)



Wayne's Journey

Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who "just likes people". When he was first told, "you might have a tumor in your bladder", he became very concerned, especially when he learned his first treatment with BCG wasn't working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.

[Learn More →](#)



Indication and Important Safety Information



Indication and Important Safety Information

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktivastg.wpenginpowered.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact ImmunityBio at 1-877-ANKTIVA (1-877-265-8482).



ANKTIVA is a Novel Treatment for NMIBC CIS Patients Unresponsive to BCG

For more information, please call 1-877-ANKTIVA

